# Clinical correlation of p16 expression with lymphatic invasion and epithelial-mesenchymal transition (EMT) in oropharyngeal carcinomas

**Authors:** Vaishak Jawahar, Saraswathy Sreeram, Jyoti Kini, Sourjya Banerjee, Athiyamaan M S, Johan Sunny, Abhishek Krishna, Challapalli Srinivas, Dilson Lobo, Paul Simon, Bharat Sai, Lanisha Sequeira, Agapiti H Chuwa

PMC · DOI: 10.12688/f1000research.160134.1 · 2025-01-22

## TL;DR

This study explores how p16 expression relates to lymphatic invasion and EMT in oropharyngeal cancer patients, finding better survival rates in p16-positive cases.

## Contribution

The study provides new clinical correlations between p16 expression, EMT markers, and survival outcomes in HPV-associated oropharyngeal carcinomas.

## Key findings

- p16-positive patients had significantly higher 1-year overall survival compared to p16-negative patients.
- HPV-associated patients presented with advanced nodal disease and higher-stage tumors at diagnosis.
- E-cadherin was expressed in all HPV-positive patients, while vimentin was absent in these cases.

## Abstract

To examine the clinical correlation of p16 expression with Epithelial–Mesenchymal Transition (EMT) markers and lymphatic invasion in OPSCC patients in terms of clinical status at presentation, subsequent progression, and survival.

Tissue blocks of biopsy-proven Oropharyngeal Squamous Cell Carcinoma were subjected to Immunohistochemistry (IHC) for evaluating the expression of p16, e-cadherin, vimentin and podoplanin. This expression pattern was correlated with the demographic details, treatment response and survival patterns.

60 patients were finally available for evaluation in this study. Prevalence of HPV infection in our study was found to be 11.7%. E-cadherin expression was found in all HPV-associated patients whereas vimentin was not expressed in any of these. 71.4% patients had low Podoplanin expression and 85.7% had low lymphatic vessel count. Among the HPV- associated patients, 85.8% had T3-T4 stage, 100% had N2-N3 disease and 95% had stage IV disease. It was also found that p16-positive patients had significantly higher 1-year Overall survival (OS) (80%, p=0.045), higher 1-year Progression-free survival (PFS) (60%) and higher 1-year Locoregional recurrence-free survival (LRRFS) (75%) when compared to p16-negative patients.

Prevalence of HPV infection was found to be similar to that of previous studies conducted in India. As previous literature suggests, the HPV-positive patients in our study presented with advanced nodal disease at presentation and thereby, an advanced overall stage. Further follow-up of these patients including their treatment details, determination of possible prognostic markers, and evaluation of their survival parameters can be done which can help in modifying the existing treatment modalities as HPV-associated OPSCC are known to have better prognosis according to literature.

## Linked entities

- **Genes:** CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029], shg (shotgun) [NCBI Gene 37386], PRELID1 (PRELI domain containing 1) [NCBI Gene 737446]

## Full-text entities

- **Genes:** CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, VIM (vimentin) [NCBI Gene 7431], PDPN (podoplanin) [NCBI Gene 10630] {aka AGGRUS, D2-40, GP36, GP40, Gp38, HT1A-1}
- **Diseases:** Oropharyngeal Squamous Cell Carcinoma (MESH:D000077195), HPV infection (MESH:D030361), stage IV disease (MESH:D007676), oropharyngeal carcinomas (MESH:D009959), N2-N3 disease (MESH:D004194)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12553974/full.md

---
Source: https://tomesphere.com/paper/PMC12553974